Publicacións en colaboración con investigadores/as de Complexo Hospitalario Universitario de Vigo (22)

2022

  1. Insulin-like Growth Factor 2 (IGF-2) and Insulin-like Growth Factor Binding Protein 7 (IGFBP-7) Are Upregulated after Atypical Antipsychotics in Spanish Schizophrenia Patients

    International Journal of Molecular Sciences, Vol. 23, Núm. 17

2021

  1. Microglia: The real foe in hiv-1-associated neurocognitive disorders?

    Biomedicines, Vol. 9, Núm. 8

  2. Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study

    European psychiatry : the journal of the Association of European Psychiatrists, Vol. 64, Núm. 1, pp. e40

2019

  1. CIBERSAM: Ten years of collaborative translational research in mental disorders

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 1, pp. 1-8

  2. Improving emotion recognition in schizophrenia with “VOICES”: An on-line prosodic self-training

    PLoS ONE, Vol. 14, Núm. 1

  3. Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain

    Revista de Psiquiatria y Salud Mental, Vol. 12, Núm. 2, pp. 92-105

  4. Patterns of Membrane Protein Clustering in Peripheral Lymphocytes as Predictors of Therapeutic Outcomes in Major Depressive Disorder

    Frontiers in Pharmacology, Vol. 10

2018

  1. Changes in membrane protein clustering in peripheral lymphocytes in an animal model of depression parallel those observed in naïve depression patients: Implications for the development of novel biomarkers of depression

    Frontiers in Pharmacology, Vol. 9, Núm. OCT

  2. Cytokines dysregulation in schizophrenia: A systematic review of psychoneuroimmune relationship

    Schizophrenia Research, Vol. 197, pp. 19-33

  3. Serotonin syndrome versus neuroleptic malignant syndrome: a case report

    Actas Espanolas de Psiquiatria

  4. The role of the gut microbiota in schizophrenia: Current and future perspectives

    World Journal of Biological Psychiatry, Vol. 19, Núm. 8, pp. 571-585

2017

  1. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial

    BMC Psychiatry, Vol. 17, Núm. 1

2015

  1. Nurses’ perceptions of medication adherence in schizophrenia: Results of the ADHES cross-sectional questionnaire survey

    Therapeutic Advances in Psychopharmacology, Vol. 5, Núm. 6, pp. 339-350

  2. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms

    International Clinical Psychopharmacology, Vol. 30, Núm. 5, pp. 265-271

2013

  1. Psychiatrists' awareness of adherence to antipsychotic medication in patients with schizophrenia: Results from a survey conducted across Europe, the Middle East, and Africa

    Patient Preference and Adherence, Vol. 7, pp. 121-132

2012

  1. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia

    Comprehensive Psychiatry, Vol. 53, Núm. 2, pp. 145-151

  2. Serotonin transporter clustering in blood lymphocytes as a putative biomarker of therapeutic efficacy in major depressive disorder

    Journal of Affective Disorders, Vol. 137, Núm. 1-3, pp. 46-55

2011

  1. Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia

    Neuropsychiatry, Vol. 1, Núm. 3, pp. 275-289

2008

  1. Desarrollo y validación de la versión corta de la Escala de Funcionamiento Social en esquizofrenia para su uso en la práctica clínica

    Actas Espanolas de Psiquiatria, Vol. 36, Núm. 2, pp. 102-110

2007

  1. An analysis of the cognitive deficit of schizophrenia based on the Piaget developmental theory

    Comprehensive Psychiatry, Vol. 48, Núm. 4, pp. 376-379